Entera Bio Ltd.
NASDAQ: ENTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Miranda J. Toledano
- Employees
- 18
- Headquarters
- Jerusalem, Israel
- IPO year
- 2018
- Market cap
- $75.9M
- Website
- https://www.enterabio.com
Loading ENTX…
Loading profile data…Frequently asked questions about ENTX
What does Entera Bio Ltd. (ENTX) do?
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism,...
Where does ENTX trade?
Entera Bio Ltd. (ENTX) trades on the NASDAQ Capital Market.
What sector is ENTX in?
Entera Bio Ltd. (ENTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Entera Bio Ltd.?
Miranda J. Toledano is the chief executive officer of Entera Bio Ltd. (ENTX).
Where is Entera Bio Ltd. headquartered?
Entera Bio Ltd. is headquartered in Israel.
Does ENTX pay a dividend?
Entera Bio Ltd. (ENTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ENTX go public?
Entera Bio Ltd. (ENTX) completed its initial public offering in 2018.